Vitti Long Haul develops investigational therapies for long COVID and pulmonary fibrosis. VL-PX10 and VL-P22 combine mesenchymal stem cells, exosomes, and biomaterials in Phase 2 trials. Patients ineligible for trials may access care through physician-supervised Expanded Access Programs. FDA-guided. https://vittilonghaul.com/